BCV
CRSP icon

Banque Cantonale Vaudoise’s CRISPR Therapeutics CRSP Stock Holding History

Banque Cantonale Vaudoise’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Buy
24,065
+6,602
+38% +$348K 0.18% 83
2026
Q1 		$831K Sell
17,463
-227
-1% -$12K 0.03% 409
2025
Q4 		$928K Buy
17,690
+127
+0.7% +$7.61K 0.03% 373
2025
Q3 		$1.14M Sell
17,563
-747
-4% -$42.9K 0.04% 342
2025
Q2 		$891K Sell
18,310
-269
-1% -$10.4K 0.04% 371
2025
Q1 		$632K Buy
+18,579
New +$788K 0.03% 425
2024
Q3 		$804K Sell
17,111
-265
-2% -$13.4K 0.03% 346
2024
Q2 		$939K Buy
17,376
+782
+5% +$45.2K 0.04% 353
2024
Q1 		$1.13M Buy
16,594
+458
+3% +$32.8K 0.04% 334
2023
Q4 		$1.01M Sell
16,136
-72
-0.4% -$3.98K 0.04% 341
2023
Q3 		$736K Sell
16,208
-158
-1% -$8.16K 0.04% 385
2023
Q2 		$918K Buy
16,366
+692
+4% +$39.3K 0.04% 367
2023
Q1 		$709K Sell
15,674
-98
-0.6% -$4.76K 0.03% 375
2022
Q4 		$641K Buy
15,772
+133
+0.9% +$7.05K 0.03% 397
2022
Q3 		$1.02M Sell
15,639
-205
-1% -$14.9K 0.06% 322
2022
Q2 		$963K Buy
15,844
+11,615
+275% +$683K 0.05% 351
2022
Q1 		$266K Buy
4,229
+786
+23% +$49.4K 0.01% 721
2021
Q4 		$261K Sell
3,443
-623
-15% -$54.4K 0.01% 764
2021
Q3 		$455K Sell
4,066
-297
-7% -$37.3K 0.02% 586
2021
Q2 		$706K Sell
4,363
-360
-8% -$43.8K 0.03% 512
2021
Q1 		$575K Sell
4,723
-5,559
-54% -$839K 0.03% 500
2020
Q4 		$1.57M Buy
10,282
+1,310
+15% +$155K 0.09% 208
2020
Q3 		$751K Buy
8,972
+308
+4% +$27.3K 0.05% 331
2020
Q2 		$637K Buy
8,664
+833
+11% +$48.7K 0.05% 329
2020
Q1 		$332K Sell
7,831
-758
-9% -$39.1K 0.03% 480
2019
Q4 		$523K Buy
+8,589
New +$469K 0.04% 448

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Banque Cantonale Vaudoise's CRSP Position: Q2 2026 in Review

Banque Cantonale Vaudoise increased its CRISPR Therapeutics (CRSP) stake by 38% in Q2 2026, buying an estimated $348K and bringing the position to 24,065 shares worth $1.31M. The position accounts for 0.18% of the portfolio, ranked #83.

Banque Cantonale Vaudoise first reported a position in CRSP in Q4 2019 and has held it in 26 quarters since. The position peaked at $1.57M in Q4 2020. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Banque Cantonale Vaudoise held 24,065 shares of CRISPR Therapeutics worth $1.31M as of Q2 2026.
  • Banque Cantonale Vaudoise bought 6,602 CRISPR Therapeutics shares in Q2 2026, an estimated $348K.
  • CRISPR Therapeutics made up 0.18% of Banque Cantonale Vaudoise's portfolio in Q2 2026, its #83 holding.
  • Banque Cantonale Vaudoise first reported a position in CRISPR Therapeutics in Q4 2019 and has held it in 26 quarters since.
  • Banque Cantonale Vaudoise's CRISPR Therapeutics position peaked at $1.57M in Q4 2020.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Banque Cantonale Vaudoise's 13F filing for Q2 2026, filed 31 Jul 2026.